Unreliable data leads to the failure of drug candidates *
The cost of these failures in terms of finances, lost time and impact on patients is enormous.
The heart of the problem lies in the preclinical models used to evaluate efficacy. These models do not translate well to human disease and are assessed using age-old, qualitative methods that often mask a molecule’s efficacy or lack thereof.
As an example; for NASH the use of pathologist-scored models provides researchers with a qualitative assessment of a molecule’s efficacy. This assessment is subjective, based on a limited area of the sample and is hugely imprecise. The lack of precision and accuracy of this analysis added to the 4-6 weeks that it takes to get this data across a whole study further erode the value of these models.
from pre-clinical stage
from clinical stage
*Failure of Investigational Drugs in Late-Stage Clinical Development and Publication of Trial Results Thomas J. Hwang, AB; Daniel Carpenter, PhD; Julie C. Laffenburger, PhD et al. JAMA Internet. Med. 2016
Biocellvia’s unique imaging technology banishes variability and brings absolute accuracy to your efficacy data
Our fully automated quantitative assessment plays a critical role by providing researchers with absolute accuracy and precision, delivering results that bring more in-depth insights into their compounds’ efficacy.
no bias to the results leading to a better decision making
Highly accurate, precise and translational
data allowing true comparisons across the development continuum
Image with augmented reality
of each quantified feature for deeper understanding
A turnkey solution!
For each therapeutic area, our specific algorithms were developed by digital imaging specialists and biologists, based on relevant histology. We identify morphometric parameters, quantify them, and interpret them, providing you with a more evident go/no-go decision for your drug candidate. This fully automated, proven and published methodology relies on field-proven-image-processing methods thereby ensuring that researchers obtain the most robust and reproducible data.
Nonalcoholic fatty liver disease (NAFLD) has appeared as the next most common chronic liver disease. It progresses to severe hepatic diseases including cirrhosis, liver failure and hepatocellular carcinoma.
Discover how Biocellvia is accelerating science with its dedicated assays supporting preclinical and clinical research!
Biocellvia’s R&D team is committed to developing new tools that deliver better preclinical and clinical data to meet your criteria.
Our team, composed of seasoned digital imaging specialists and biologists ensure that clinically and biologically relevant parameters are quantified.